Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
49
CSBR Quote, Financials, Valuation and Earnings
Last price:
$6.91
Seasonality move
:
56.88%
Day range:
$6.59 - $6.71
52-week range:
$5.59 - $11.99
Dividend yield:
0%
P/E ratio:
40.32x
P/S ratio:
1.62x
P/B ratio:
22.34x
Volume:
8.1K
Avg. volume:
18.3K
1-year change:
-31.11%
Market cap:
$93.2M
Revenue:
$56.9M
EPS (TTM):
$0.17
Analysts' Opinion
-
Consensus RatingChampions Oncology, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $12.00, Champions Oncology, Inc. has an estimated upside of 78.84% from its current price of $6.71.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $12.00 representing 100% downside risk from its current price of $6.71.
Fair Value
-
According to the consensus of 1 analyst, Champions Oncology, Inc. has 78.84% upside to fair value with a price target of $12.00 per share.
CSBR vs. S&P 500
-
Over the past 5 trading days, Champions Oncology, Inc. has underperformed the S&P 500 by -4.66% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Champions Oncology, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Champions Oncology, Inc. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Champions Oncology, Inc. reported revenues of $15M.
Earnings Growth
-
Champions Oncology, Inc. earnings have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Champions Oncology, Inc. reported earnings per share of $0.02.
Enterprise value:
90.1M
EV / Invested capital:
9.35x
Price / LTM sales:
1.62x
EV / EBIT:
36.60x
EV / Revenue:
1.54x
PEG ratio (5yr expected):
-0.24x
EV / Free cash flow:
15.98x
Price / Operating cash flow:
16.76x
Enterprise value / EBITDA:
22.70x
Gross Profit (TTM):
$27.8M
Return On Assets:
8.16%
Net Income Margin (TTM):
4.16%
Return On Equity:
68.71%
Return On Invested Capital:
24.74%
Operating Margin:
1.23%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-10-31 | 2024-10-31 | 2025-10-31 | 2024-10-31 | 2025-10-31 | |
| Income Statement | ||||||
| Revenue | $50M | $53.6M | $58.4M | $13.5M | $15M | |
| Gross Profit | $20.6M | $23.6M | $27.8M | $5.7M | $7.4M | |
| Operating Income | -$8.7M | -$352K | $2.5M | $732K | $185K | |
| EBITDA | -$6.2M | $1.7M | $4M | $1.1M | $542K | |
| Diluted EPS | -$0.71 | -$0.05 | $0.17 | $0.05 | $0.02 | |
| Period Ending | 2021-10-31 | 2022-10-31 | 2023-10-31 | 2024-10-31 | 2025-10-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $13.7M | $20.6M | $14M | $14.1M | $21.3M | |
| Total Assets | $29.3M | $36.4M | $28.3M | $25.2M | $30.2M | |
| Current Liabilities | $12.5M | $18.7M | $21M | $18.9M | $22.1M | |
| Total Liabilities | $21.2M | $27.2M | $28.2M | $24.6M | $25.9M | |
| Total Equity | $8.1M | $9.2M | $93K | $681K | $4.2M | |
| Total Debt | $8.5M | $7.8M | $6.8M | $5.7M | $3.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-10-31 | 2024-10-31 | 2025-10-31 | 2024-10-31 | 2025-10-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$2.5M | -$2.7M | $6.2M | -$283K | -$1.7M | |
| Cash From Investing | -$2.3M | -$109K | -$583K | -$94K | -$242K | |
| Cash From Financing | -$457K | $57K | $122K | $239K | $168K | |
| Free Cash Flow | -$4.9M | -$2.8M | $5.6M | -$377K | -$2M | |
CSBR
Sector
Market Cap
$93.2M
$28.1M
Price % of 52-Week High
55.96%
50.9%
Dividend Yield
0%
0%
Shareholder Yield
0.14%
-1.55%
1-Year Price Total Return
-31.11%
-19.36%
Beta (5-Year)
0.353
0.498
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$6.95
200-day SMA
Sell
Level
$7.05
Bollinger Bands (100)
Buy
Level
6.33 - 7.07
Chaikin Money Flow
Sell
Level
-45.6K
20-day SMA
Buy
Level
$6.67
Relative Strength Index (RSI14)
Sell
Level
49.35
ADX Line
Buy
Level
28.27
Williams %R
Neutral
Level
-72.1228
50-day SMA
Buy
Level
$6.70
MACD (12, 26)
Buy
Level
0.08
25-day Aroon Oscillator
Buy
Level
32
On Balance Volume
Neutral
Level
12.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.8104)
Sell
CA Score
(Annual)
Level (-1.1011)
Buy
Beneish M-Score
(Annual)
Level (-2.7326)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (2.4039)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.
Stock Forecast FAQ
In the current month, CSBR has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CSBR average analyst price target in the past 3 months is $12.00.
-
Where Will Champions Oncology, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Champions Oncology, Inc. share price will rise to $12.00 per share over the next 12 months.
-
What Do Analysts Say About Champions Oncology, Inc.?
Analysts are divided on their view about Champions Oncology, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Champions Oncology, Inc. is a Sell and believe this share price will drop from its current level to $12.00.
-
What Is Champions Oncology, Inc.'s Price Target?
The price target for Champions Oncology, Inc. over the next 1-year time period is forecast to be $12.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CSBR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Champions Oncology, Inc. is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of CSBR?
You can purchase shares of Champions Oncology, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Champions Oncology, Inc. shares.
-
What Is The Champions Oncology, Inc. Share Price Today?
Champions Oncology, Inc. was last trading at $6.91 per share. This represents the most recent stock quote for Champions Oncology, Inc.. Yesterday, Champions Oncology, Inc. closed at $6.71 per share.
-
How To Buy Champions Oncology, Inc. Stock Online?
In order to purchase Champions Oncology, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get CSBR Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CSBR
Sector
P/E ratio
40.32x
24.09x
PEG ratio
-0.24x
-0.01x
P/B ratio
22.34x
1.83x
Price / LTM sales
1.62x
1.59x
Growth Metrics
CSBR
Sector
Revenue growth
11.46%
4.68%
Earnings growth
-64.36%
10.88%
Revenue (5-year growth)
12.13%
6.45%
Earnings forecast
--
-$0.18
Profitability
CSBR
Sector
Profitability FY 2025
$26.9M
$3.6M
Return on invested capital
24.74%
-31.87%
Return on assets
8.16%
-28.18%
Return on equity
68.71%
-37.89%
Earnings Date
Last Earnings Date
Dec
15
Next Earnings Date
Mar
11
Estimated Next Earnings Date
Mar
16
Balance Sheet
CSBR
Sector
Total cash
$8.5M
$26.2M
Short term investments
--
$25.7M
Total assets
$32.3M
$76.7M
Long term debt
$3.9M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 36x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
73
INOD alert for Jan 6
Innodata, Inc. [INOD] is up 21.69% over the past day.
Buy
65
AVAV alert for Jan 6
AeroVironment, Inc. [AVAV] is up 23.1% over the past day.
Buy
62
OKLO alert for Jan 6
Oklo, Inc. [OKLO] is up 14.86% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
